The global HIV Drugs & Injectables market is projected to grow at a CAGR of 4.6 % by 2034
The HIV Drugs & Injectables Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Demand for Newer Drugs Poses a Challenge for Generic Manufacturers
The patients undergoing HIV treatment regimens prefer to take newly launched drugs over the previous blockbuster HIV drugs or generic drugs owing to fact that new drugs tend to be safer with fewer side-effects and are less likely to develop early drug resistance due to which very limited generic drug manufacturers are operating in this sector. The three major players of generic HIV drugs market include Aurobindo, Cipla and Mylan. These companies are capable of manufacturing a wide range of generics and can generate profits despite decline in demand, while it becomes difficult for small generic manufacturers. Thus, fast changing drug science and new drug launches make certain drugs obsolete for example in recent years few of the blockbuster drugs such as Crixivan (indinavir), Invirase (saquinavir), Rescriptor (delaviridine), Videx (didanosine) Viracept (nelfinavir), and Zerit (stavudine) have all been removed from the market. Moreover, some of the innovator companies are also signing pay for delay pact with the generic firms to delay the launch of generics in the market and retain their monopolistic status.
Lack of Trained Staff and Infrastructural Facilities
There has been a growing demand for LAI for HIV treatment and PrEP however pressing needs pertaining training, staffing, storage and refrigeration in certain cases have been a major hurdle for implementing LA HIV regimens. Private groups do not staff nurses and might need to hire nurses and storage systems for administration of these injectables. Role of pharmacies and HIV care systems through its existing networks needs to be considered for widescale deployment of LAIs. Post pandemic there has been a rise in administration of wide variety of medication classes by the pharmacy staff. These pharmacies and community-based drugstores can be commissioned to delivery of LAI by pharmacy staff, while policymakers can incentivize these services offered at these places. Moreover, changes in electronic health record systems, restructuring of the clinic visits needs to be spanned out for effective and smooth implementation of LAI injectables for HIV.
What Questions Should You Ask before Buying a Market Research Report?
How is the HIV Drugs & Injectables market evolving?
What is driving and restraining the HIV Drugs & Injectables market?
How will each HIV Drugs & Injectables submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
How will the market shares for each HIV Drugs & Injectables submarket develop from 2024 to 2034?
What will be the main driver for the overall market from 2024 to 2034?
Will leading HIV Drugs & Injectables markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
Who are the leading players and what are their prospects over the forecast period?
What are the HIV Drugs & Injectables projects for these leading companies?
How will the industry evolve during the period between 2024 and 2034? What are the implications of HIV Drugs & Injectables projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the HIV Drugs & Injectables market?
Where is the HIV Drugs & Injectables market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the HIV Drugs & Injectables market today, and over the next 10 years:
Our This 288-page report provides 118 tables, 188 charts exclusively to you.
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2034 and other analyses reveal commercial prospects
In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising HIV Drugs & Injectables prices and recent developments.
Segments Covered in the Report
Drug Class
Combination Therapies (Inclu. InSTI)
Nucleoside and Non-Nucleoside RTIs
Protease Inhibitors
Oral Drugs
Biktarvy
Complera
Delstrigo
Dovato
Genvoya
Juluca
Odefsey
Stribild
Symtuza
Triumeq
Descovy
Truvada
Edurant
Pilfreto
Rukobia
Prezista
Isentress
Tivicay
Long-Acting Injectables
Cabuneva
Sunlenca
Trogarzo
Enfuvirtide
Pre-Exposure Prophylaxis Injectables
Apretude
Lencapavir
Drug Type
Branded
Generics
Distribution Channels
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:
North America
U.S.
Canada
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
MEA
GCC
South Africa
Rest of MEA
The report also includes profiles for some of the leading companies in the HIV Drugs & Injectables Market, 2024 to 2034, with a focus on this segment of these companies' operations.
Leading companies profiled in the report
AbbVie Inc.
Bristol Myers Squibb
Frontier Biotechnologies
Gilead Sciences
J&J Innovation Medicine
Merck KGaA
Teva Pharmaceuticals
Theratechnologies
ViiV Healthcare (a GSK Company)
Overall world revenue for HIV Drugs & Injectables Market, 2024 to 2034 in terms of value the market will surpass US$35 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the HIV Drugs & Injectables Market, 2024 to 2034 report help you?
In summary, our 280+ page report provides you with the following knowledge:
Revenue forecasts to 2034 for HIV Drugs & Injectables Market, 2024 to 2034, with forecasts for drug class, oral drug, long acting injectables, PrEP injectables, drug type and distribution channels, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the HIV Drugs & Injectables Market, 2024 to 2034 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 9 of the major companies involved in the HIV Drugs & Injectables Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the HIV Drugs & Injectables Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
Table of Contents
1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to HIV Drugs & Injectables Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who is This Report for?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Visiongain Reports
- 1.10 About Visiongain
2 Executive Summary
3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.3 Impact Analysis
- 3.3.1 Market Driving Factors
- 3.3.1.1 U.S. Targets to End the HIV Epidemic in the Country by 2030
- 3.3.1.2 Failure for Adherence of Oral HIV Treatment Regimen to drive HIV Injectables Market
- 3.3.1.3 Long-Acting PrEP will Drive in HIV Prevention Drugs Market
- 3.3.1.4 Technological Collaborations to Drive the Growth of Long Acting Injectables
- 3.3.2 Market Restraining Factors
- 3.3.2.1 Demand for Newer Drugs Possess a Challenge for Generic Manufacturers
- 3.3.2.2 Needle Fear and Medical Mistrust
- 3.3.2.3 Social Stigma
- 3.3.2.4 Lack of Trained Staff & Infrastructural Facilities
- 3.3.3 Market Opportunities
- 3.3.3.1 Demand for Self-Administrating Injectables
- 3.3.3.2 Broadly Neutralizing Antibodies (bNAbs)
- 3.4 COVID-19 Impact Analysis
- 3.5 Supply Chain Analysis
- 3.5.1 Raw Material Suppliers
- 3.5.2 Manufacturers
- 3.5.3 Procurement Agents
- 3.5.4 Distributors
- 3.5.5 Service Providers
- 3.6 Regulatory Framework
- 3.7 Porter's Five Forces Analysis
- 3.7.1 Bargaining Power of Suppliers
- 3.7.2 Bargaining Power of Buyers
- 3.7.3 Competitive Rivalry
- 3.7.4 Threat of Substitutes
- 3.7.5 Threat of New Entrants
- 3.8 PEST Analysis
- 3.9 Emerging Markets and Megatrends
- 3.9.1.1 Artificial Intelligence in HIV Drug Discovery & Treatment
- 3.9.1.2 Gene Editing Technologies
- 3.9.1.3 Nano pharmaceutical drug delivery technologies
4 HIV Drugs & Injectables Market Analysis by Drug Class
- 4.1 Key Findings
- 4.2 HIV Drugs & Injectables Segment, By Drug Class: Market Attractiveness Index
- 4.3 HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Class
- 4.4 Combination Therapies (Inclu. InSTI)
- 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
- 4.4.2 Market Share by Region, 2024 & 2034 (%)
- 4.5 Nucleoside and Non-Nucleoside RTIs
- 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
- 4.5.2 Market Share by Region, 2024 & 2034 (%)
- 4.6 Protease Inhibitors
- 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
- 4.6.2 Market Share by Region, 2024 & 2034 (%)
5 HIV Therapeutics Oral Drugs Market
- 5.1 Key Findings
- 5.2 Indication Segment: Market Attractiveness Index
- 5.3 HIV Oral Drugs Market Size Estimation and Forecast by Branded Drugs
- 5.4 Biktarvy
- 5.5 Complera
- 5.6 Delstrigo
- 5.7 Dovato
- 5.8 Genvoya
- 5.9 Juluca
- 5.10 Odefsey
- 5.11 Stribild
- 5.12 Symtuza
- 5.13 Triumeq
- 5.14 Descovy
- 5.15 Truvada
- 5.16 Edurant
- 5.17 Pifeltro
- 5.18 Rukobia
- 5.19 Prezista
- 5.20 Isentress
- 5.21 Tivicay
6 HIV Therapeutics Long-Acting Injectable Market, By Drugs
- 6.1 Key Findings
- 6.2 Indication Segment: Market Attractiveness Index
- 6.3 HIV LA & Injectable Drug Market Size Estimation and Forecast by Drugs
- 6.4 Cabenuva
- 6.4.1 Cabenuva Market Size, 2024-2034 (US$ Billion)
- 6.5 Sunlenca
- 6.6 Trogarzo
- 6.7 Enfuvirtide (Generic)
7 HIV Pre-Exposure Prophylaxis (PrEP) Injectable Market, By Drugs
- 7.1 Key Findings
- 7.2 HIV Pre-Exposure Prophylaxis (PrEP) Market Size Estimation and Forecast by Drugs
- 7.3 Apretude
- 7.3.1 Apretude Market Size, 2024-2034 (US$ Billion)
- 7.4 Lenacapavir (PrEP)
- 7.4.1 Lenacapavir Market Size, 2024-2034 (US$ Billion)
8 HIV Injectables Market Analysis by Oral Drug Types
- 8.1 Key Findings
- 8.2 HIV Oral Drugs Segment, By Types: Market Attractiveness Index
- 8.3 HIV Oral Drugs Market Size Estimation and Forecast by Drug Types
- 8.4 Branded
- 8.4.1 Market Size by Region, 2024-2034 (US$ Billion)
- 8.4.2 Market Share by Region, 2024 & 2034 (%)
- 8.5 Generics
- 8.5.1 Market Size by Region, 2024-2034 (US$ Billion)
- 8.5.2 Market Share by Region, 2024 & 2034 (%)
9 Global HIV Drugs & Injectables Market Analysis by Distribution Channel
- 9.1 Key Findings
- 9.2 HIV Drugs & Injectables Segment, By Distribution Channel: Market Attractiveness Index
- 9.3 HIV Drugs & Injectables Size Estimation and Forecast by Distribution Channel
- 9.4 Hospital Pharmacies
- 9.4.1 Market Size by Region, 2024-2034 (US$ Billion)
- 9.4.2 Market Share by Region, 2024 & 2034 (%)
- 9.5 Retail Pharmacies
- 9.5.1 Market Size by Region, 2024-2034 (US$ Billion)
- 9.5.2 Market Share by Region, 2024 & 2034 (%)
- 9.6 Online Pharmacies
- 9.6.1 Market Size by Region, 2024-2034 (US$ Billion)
- 9.6.2 Market Share by Region, 2024 & 2034 (%)
10 HIV Injectables Market Analysis by Pipeline Analysis
11 HIV Injectables Market Analysis by Regional Share (%) Analysis
- 11.1 Key Findings
- 11.2 Regional Market Size Estimation and Forecast
12 North America HIV Drugs & Injectables Market Analysis
- 12.1 Key Findings
- 12.2 North America HIV Drugs & Injectables Market Attractiveness Index
- 12.3 North America HIV Drugs & Injectables Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 12.4 North America HIV Drugs & Injectables Market Size Estimation and Forecast by Country
- 12.5 North America HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Type
- 12.6 North America HIV Drugs & Injectables Market Size Estimation and Forecast by Oral Drug Type
- 12.7 North America HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Class
- 12.8 North America HIV Drugs & Injectables Market Size Estimation and Forecast by Distribution Channel
- 12.9 U.S. HIV Drugs & Injectables Market Analysis
- 12.10 Canada HIV Drugs & Injectables Market Analysis
13 Europe Decentralised Clinical Trials Market Analysis
- 13.1 Key Findings
- 13.2 Europe HIV Drugs & Injectables Market Attractiveness Index
- 13.3 Europe HIV Drugs & Injectables Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 13.4 Europe HIV Drugs & Injectables Market Size Estimation and Forecast by Country
- 13.5 Europe HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Type
- 13.6 Europe HIV Drugs & Injectables Market Size Estimation and Forecast by Oral Drug Type
- 13.7 Europe HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Class
- 13.8 Europe HIV Drugs & Injectables Market Size Estimation and Forecast by Distribution Channel
- 13.9 UK HIV Drugs & Injectables Market Analysis
- 13.10 Germany HIV Drugs & Injectables Trials Market Analysis
- 13.11 France HIV Drugs & Injectables Trials Market Analysis
- 13.12 Italy HIV Drugs & Injectables Trials Market Analysis
- 13.13 Spain HIV Drugs & Injectables Trials Market Analysis
- 13.14 Rest of Europe HIV Drugs & Injectables Trials Market Analysis
14 Asia-Pacific HIV Drugs & Injectables Market Analysis
- 14.1 Key Findings
- 14.2 Asia-Pacific HIV Drugs & Injectables Market Attractiveness Index
- 14.3 Asia-Pacific HIV Drugs & Injectables Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 14.4 Asia-Pacific HIV Drugs & Injectables Market Size Estimation and Forecast by Country
- 14.5 Asia-Pacific HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Type
- 14.6 Asia-Pacific HIV Drugs & Injectables Market Size Estimation and Forecast by Oral Drug Type
- 14.7 Asia-Pacific HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Class
- 14.8 Asia-Pacific HIV Drugs & Injectables Market Size Estimation and Forecast by Distribution Channel
- 14.9 China HIV Drugs & Injectables Market Analysis
- 14.10 India HIV Drugs & Injectables Market Analysis
- 14.11 Japan HIV Drugs & Injectables Market Analysis
- 14.12 Australia HIV Drugs & Injectables Market Analysis
- 14.13 South Korea HIV Drugs & Injectables Market Analysis
- 14.14 Rest of Asia HIV Drugs & Injectables Market Analysis
15 Latin America HIV Drugs & Injectables Market Analysis
- 15.1 Key Findings
- 15.2 Latin America HIV Drugs & Injectables Market Attractiveness Index
- 15.3 Latin America HIV Drugs & Injectables Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 15.4 Latin America HIV Drugs & Injectables Market Size Estimation and Forecast by Country
- 15.5 Latin America HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Type
- 15.6 Latin America HIV Drugs & Injectables Market Size Estimation and Forecast by Oral Drug Type
- 15.7 Latin America HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Class
- 15.8 Latin America HIV Drugs & Injectables Market Size Estimation and Forecast by Distribution Channel
- 15.9 Brazil HIV Drugs & Injectables Market Analysis
- 15.10 Mexico HIV Drugs & Injectables Market Analysis
- 15.11 Rest of Latin America HIV Drugs & Injectables Market Analysis
16 MEA HIV Drugs & Injectables Market Analysis
- 16.1 Key Findings
- 16.2 MEA HIV Drugs & Injectables Market Attractiveness Index
- 16.3 MEA HIV Drugs & Injectables Market by Country, 2024, 2029 & 2034 (US$ Billion)
- 16.4 MEA HIV Drugs & Injectables Market Size Estimation and Forecast by Country
- 16.5 MEA HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Type
- 16.6 MEA HIV Drugs & Injectables Market Size Estimation and Forecast by Oral Drug Type
- 16.7 MEA HIV Drugs & Injectables Market Size Estimation and Forecast by Drug Class
- 16.8 MEA HIV Drugs & Injectables Market Size Estimation and Forecast by Distribution Channel
- 16.9 South Africa HIV Drugs & Injectables Market Analysis
- 16.10 GCC HIV Drugs & Injectables Market Analysis
- 16.11 Rest of MEA HIV Drugs & Injectables Market Analysis
17 Company Profiles
- 17.1 Competitive Landscape, 2023
- 17.2 Strategic Outlook
- 17.3 ViiV Healthcare (a GSK company)
- 17.3.1 Company Snapshot
- 17.3.2 Company Overview
- 17.3.3 Financial Analysis
- 17.3.3.1 Net Revenue, 2018-2023
- 17.3.3.2 R&D, 2018-2023
- 17.3.3.3 Regional Market Shares, 2022
- 17.3.4 Product Benchmarking
- 17.3.5 Strategic Outlook
- 17.3.6 SWOT Analysis
- 17.4 Gilead Sciences, Inc.
- 17.4.1 Company Snapshot
- 17.4.2 Company Overview
- 17.4.3 Financial Analysis
- 17.4.3.1 Net Revenue, 2018-2023
- 17.4.3.2 R&D, 2018-2023
- 17.4.3.3 Regional Market Shares, 2023
- 17.4.4 Product Benchmarking
- 17.4.5 Strategic Outlook
- 17.4.6 SWOT Analysis
- 17.5 Merck KGaA
- 17.5.1 Company Snapshot
- 17.5.2 Company Overview
- 17.5.3 Financial Analysis
- 17.5.3.1 Net Revenue, 2018-2023
- 17.5.3.2 R&D, 2018-2023
- 17.5.3.3 Regional Market Shares, 2023
- 17.5.4 Product Benchmarking
- 17.5.5 Strategic Outlook
- 17.5.6 SWOT Analysis
- 17.6 AbbVie Inc.
- 17.6.1 Company Snapshot
- 17.6.2 Company Overview
- 17.6.3 Financial Analysis
- 17.6.3.1 Net Revenue, 2018-2023
- 17.6.3.2 R&D, 2018-2023
- 17.6.3.3 Regional Market Shares, 2023
- 17.6.4 Product Benchmarking
- 17.6.5 Strategic Outlook
- 17.7 J&J Innovative Medicine ( formerly Janssen Pharma)
- 17.7.1 Company Snapshot
- 17.7.2 Company Overview
- 17.7.3 Financial Analysis
- 17.7.3.1 Net Revenue, 2018-2023
- 17.7.3.2 R&D, 2018-2023
- 17.7.3.3 Regional Market Shares, 2023
- 17.7.4 Product Benchmarking
- 17.7.5 Strategic Outlook
- 17.8 Theratechnologies Inc.
- 17.8.1 Company Snapshot
- 17.8.2 Company Overview
- 17.8.3 Financial Analysis
- 17.8.3.1 Net Revenue, 2018-2023
- 17.8.3.2 R&D, 2018-2023
- 17.8.3.3 Regional Market Shares, 2023
- 17.8.4 Product Benchmarking
- 17.8.5 Strategic Outlook
- 17.9 Teva Pharmaceuticals Inc.
- 17.9.1 Company Snapshot
- 17.9.2 Company Overview
- 17.9.3 Financial Analysis
- 17.9.3.1 Net Revenue, 2018-2023
- 17.9.3.2 R&D, 2018-2023
- 17.9.3.3 Regional Market Shares, 2023
- 17.9.4 Product Benchmarking
- 17.10 Frontier Biotechnologies Inc.
- 17.10.1 Company Snapshot
- 17.10.2 Company Overview
- 17.10.3 Product Benchmarking
- 17.10.4 Strategic Outlook
- 17.11 Bristol Myers Squibb Inc.
- 17.11.1 Company Snapshot
- 17.11.2 Company Overview
- 17.11.3 Financial Analysis
- 17.11.3.1 Net Revenue, 2018-2023
- 17.11.3.2 R&D, 2018-2023
- 17.11.3.3 Regional Market Shares, 2023
- 17.11.4 Product Benchmarking
- 17.11.5 Strategic Outlook
18 Conclusion and Recommendations
- 18.1 Recommendations for Market Players
- 18.2 Recommendations for Market Players
